Plasma levels of interleukin (IL)-6, soluble IL-6 receptor, soluble gp130, leukemia inhibitory factor (LIF), and ciliary neutrophic factor (CNTF) were analyzed in 32 patients with severe malaria. Ten had renal failure, 8 had cerebral malaria, and 14 had other causes of severity. Before treatment, the IL-6 and soluble IL-6 receptor plasma levels were significantly higher in persons with cerebral malaria or renal failure than in other groups ( for both). After P ! .01 initiation of therapy, IL-6 levels dropped within 24 h, but soluble IL-6 receptor levels increased. CNTF levels were significantly reduced in persons with cerebral malaria or renal failure but normalized within 24 h. Plasma concentrations of gp130 and LIF did not differ between the malaria groups or normal controls. Excessive levels of IL-6 could be controlled by a subsequent shedding of the soluble IL-6 receptor, and low-level CNTF expression could contribute to or even result from cerebral malaria or renal failure.
IL-6 family [8] . This sharing is consistent with functional redundancy among the IL-6-related cytokine family.
In this study, we determined plasma concentrations of members of the IL-6 cytokine family (IL-6, LIF, CNTF), the soluble IL-6 receptor (sIL-6R), and the gp130 receptor subunit in 32 patients with severe Plasmodium falciparum malaria in Bangkok. The relation of these parameters to disease severity and plasma levels of TNF and of the TNF receptor were determined.
Methods
Patients and controls. We studied 32 patients who met World Health Organization criteria for severe P. falciparum malaria. Cerebral malaria (CM) was defined as unrousable coma not attributable to any other cause in a patient with P. falciparum malaria. Renal failure (RF) was defined as urine output of !400 mL/24 h or serum creatinine 13 .0 mg/dL [9] . All patients were of Thai origin and from a population in which malaria is not endemic. Clinical disease severity was estimated by APACHE (acute physiology and chronic healthy evolution) II score. Local laboratory personnel were the healthy controls ( ). n ϭ 16 Antimalarial treatment. All patients received standard antimalarial treatment with artesunate (120 mg statim intravenously and 60 mg every 12 h to 600 mg total). Parasite clearance times were calculated from initiation of treatment until the first time that peripheral blood films were negative for asexual parasites. Fever clearance times were calculated from initiation of treatment until normalization of body temperature.
Laboratory assessments. For routine patient care, parasite counts were done 4 times a day (6-h intervals) until blood films were negative on 3 consecutive examinations by Giemsa-stained thick smears. Blood samples for the determination of cytokines and receptors were obtained before and after initiation of treatment at 6, 12, 24, 48, and 96 h after therapy. The blood specimens were centrifuged, and EDTA-plasma was separated and immediately frozen at Ϫ70ЊC. The samples were shipped to Austria on dry ice. Plasma levels of IL-6, IL-6 receptor, TNF, soluble TNF receptor (sTNFR; 55 kDa), LIF, CNTF, and gp130 were determined by ELISA (R&D Systems, Minneapolis). All assays were performed according to manufacturers' instructions. In normal controls, the median (range) plasma levels were as follows: TNF, 4.4 (0.1-8.3) pg/mL; sTNFR (55 kDa), 1014 (678-1546) pg/mL; IL-6, 3.0 (1.1-6.4) pg/mL; IL-6 receptor, 11.4 (6.9-18.2) pg/mL; and gp130, 2.6 (1.3-4.5) ng/mL. In the 16 healthy subjects, LIF was measured in 4, and CNTF was measured in 13 (81%). The median plasma levels of CNTF and LIF in normal subjects were 5.7 (0-13) and 4.3 (3-7.2) pg/mL, respectively.
Statistical analysis. For comparisons of patient groups and healthy controls and serum levels at different time points, Wilcoxon rank sum tests and Kruskall-Wallis tests were used. For correlation analysis, we used Spearman's test. All analyses were two-sided, and differences with were considered significant. P ! .01
Results

Patients.
Of patients with malaria, 10 had RF, 8 had CM, and 15 had various types of severe malaria. Of the latter, 5 had hyperparasitemia, 4 had jaundice (bilirubin 13.0 mg/dL), 2 had hyperpyrexia (rectal temperature 140ЊC), 2 had hypoglycemia (blood sugar !40 mg/dL), and 1 had circulatory collapse (systolic blood pressure !70 mm Hg). These patients (noncerebral, nonrenal malaria) were grouped together as representing "moderate severe malaria" (MSM). The APACHE II score was significantly higher in RF (median [range], 14 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] ) and CM (20 Table 1 . Characteristics and plasma levels (median, range) of leukemia inhibitory factor (LIF) and ciliary neutrophic factor (CNTF) of 32 patients with severe P. falciparum infection. ). No differences between the maximal plasma cytokine con-.05 centrations or kinetics were seen between patients with RF or CM. Thus, these patients were grouped together as representing "severe complicated malaria" (SCM).
Plasma levels of IL-6 and sIL-6R. Plasma cytokine levels of IL-6 and sIL-6R are shown in figure 1 . No significant difference between SCM and MSM groups was seen before therapy ( ). However, in MSM patients, IL-6 levels dropped P ϭ .614 faster than in SCM patients ( after 6 h) and were normal P ϭ .04 96 h after the start of therapy (median [range], 1.8 [0.1-4.6] pg/ mL), whereas in SCM, plasma IL-6 levels remained elevated (25.2 [1.4-48.9] pg/mL). Plasma sIL-6R was elevated in both groups compared with normal controls. There was no significant difference between groups prior to treatment. After initiation of therapy, plasma sIL-6R levels increased and were elevated compared with pretreatment values after 48 h. There was a significant correlation between parasite clearance time ( ), but no relation to other cytokine levels was seen. r ϭ 0.619
Plasma TNF and sTNFR. Plasma TNF levels and sTNFR were significantly elevated before treatment in both groups compared with healthy controls. Patients with SCM had higher concentrations of TNF and sTNFR than patients with MSM ( for all comparisons; figure 1). A significant correlation P ! .01 between TNF and sTNFR levels was seen ( ); in adr ϭ 0.672 dition, both parameters were related to plasma IL-6 concentrations ( and 0.599). r ϭ 0.567 Plasma levels of LIF, CNTF, and gp130. No differences in positive LIF or in LIF plasma levels were seen in patients with RF, CM, and MSM and in normal controls (table 1) . In addition, no differences in LIF detection or in LIF levels during and after therapy were seen for all groups (data not shown). In contrast, plasma CNTF levels were significantly depressed in patients with RF or CM compared with persons with MSM and healthy controls (table 1) . However, 24 h after the start of therapy, CNTF levels were similar in all groups (data not shown). LIF plasma levels were inversely related to parasitemia ( ), TNF ( ), sTNFR ( ), and r ϭ Ϫ0.714 r ϭ Ϫ0.678 r ϭ Ϫ0.572 IL-6 ( ). We also detected a correlation between LIF r ϭ Ϫ0.758 and both platelet count and fever before treatment (r ϭ 0.694 and 0.787, respectively). No differences were seen in gp130 plasma levels between the 3 patient groups and controls. In addition, gp130 levels did not change significantly during the observation period (data not shown).
Discussion
We determined plasma levels of TNF-a, sTNFR, IL-6, sIL6r, LIF, CNTF, and gp-130 in nonimmune patients with severe P. falciparum malaria to elucidate possible interactions and/or synergism of different members of the IL-6-cytokine family with indices of disease severity. As expected, plasma concentrations of TNF and sTNFR were significantly elevated in all 3 patientgroups (CM, RF, MSM). The highest concentrations were in patients with CM or RF, which is similar to previous findings [1, 10] .
IL-6 is also a sensitive marker of severity, the time course of raised concentrations perhaps being of greater significance than a single value [1] . In addition, although TNF can initiate the synthesis of IL-6, experimental inhibition of TNF by pentoxifylline suggests that some IL-6 production can occur independently of TNF [11] . In the current study, the half life for both TNF and IL-6 plasma concentrations were similar (figure 1). However, in contrast to TNF, no differences in IL-6 concentrations were seen in the 3 patient groups before therapy.
Soluble forms of both the IL-6 receptor and gp130 can inhibit sIL-6R or gp130-mediated cytokine activities in vitro [2] . In our patients, levels of sIL-6R were significantly elevated in all patients before therapy and increased further after the decline in plasma IL-6 levels and clinical improvement. This suggests, similar to the relation of TNF and sTNFR [10] , a naturally occurring control for the excessive release of IL-6. On the other hand, the correlation between serum levels of sIL-6R and parasite clearance time could underline the pivotal role for IL-6 in effective parasite clearance.
In severe malaria, serum levels of the gp130 receptor subunit were not different from those of normal subjects. Thus, it appears that this mechanism is not involved in the control of the effects of excessive IL-6 concentrations, possibly because sIL-6R can specifically bind to circulating IL-6, whereas the gp130 subunit is shared among other receptors [2, 3, [6] [7] [8] . LIF has been detected in several inflammatory conditions, including kidney allograft rejection, giant cell arteritis, and septicemia [4, 12] . In two studies of septicemia, LIF was detected in 11 of 31 patients [4] and in 8 of 90 patients [12] ; the two studies used different ELISAs. Low levels of LIF were detected in 9 of 32 patients with severe malaria, but also in 4 of 16 control subjects in this study. The detection limit of our assay was 2 pg/mL, as opposed to 56 pg/mL in the assays used in the sepsis studies, which could explain the positive detection in healthy controls in our study. In septicemia, high LIF concentrations (100-37,000 pg/mL) were related to higher mortality and shorter survival [4] . In contrast, in malaria, an inverse correlation to indices of severity, such as parasite counts and thrombocytopenia, suggests a benefit. This difference could be related to the pleiotropic activity of this cytokine, including not only acutephase protein synthesis, but also bone resorption, lipid metabolism, early embryogenesis, and megakaryozytopoesis [3] . Since mice with endotoxic shock had no circulating LIF, but LIFmRNA was detectable in tissues by polymerase chain reaction [13] , the difference in LIF detection between patients with septicemia and malaria remains to be elucidated.
CM results in multiple substantially unpredictable neuropsychiatric sequelae [14, 15] . CNTF has demonstrated activity as a survival and differentiation factor for cells of the nervous system [6] . In CM and in RF, CNTF levels were significantly lower than in persons with MSM or healthy subjects and normalized within 24-48 h. Normal CNTF expression could prevent neuron damage in malaria, and low CNTF expression could predispose for CM. However, since reduced CNTF levels were seen in both patients with CM and RF, its down-regulation may be systemic rather than organ-specific.
We conclude that the high expression of IL-6 could be controlled by a subsequent shedding of the sIL-6R but not the gp130 subunit, which is shared among other cytokines of the IL-6 family. In contrast to septicemia, plasma LIF levels were not affected by severe malaria. Whether low-level expression of CNTF in CM or RF affects disease outcome remains to be determined.
